To the full analysis
Amdocs stock: growth
DOXAmdocs reported $4.7B in revenue for fiscal 2026, up 3.6% on the prior year, up 1.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
2.7%
per year from 2007 to 2026, per share 6.4%
Earnings (Annual rate)
1.7%
per year from 2007 to 2026, per share 5.3%
Free cash flow (Annual rate)
4.2%
per year from 2007 to 2026, per share 8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 1.8% | 2.4% | 2.7% |
| Revenue per share | 5.6% | 5.9% | 6.4% |
| Earnings | −6.1% | 2.0% | 1.7% |
| Earnings per share | −2.6% | 5.5% | 5.3% |
| Free cash flow | −4.7% | 1.4% | 4.2% |
| Free cash flow per share | −1.2% | 4.9% | 8.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $2.84B | $364.94M | $257.57M |
| 2008 | $3.16B | $378.91M | $347.8M |
| 2009 | $2.86B | $326.18M | $435.83M |
| 2010 | $2.98B | $343.91M | $598.25M |
| 2011 | $3.18B | $346.67M | $425.71M |
| 2012 | $3.25B | $391.37M | $392.02M |
| 2013 | $3.35B | $412.44M | $563.82M |
| 2014 | $3.56B | $422.12M | $597.69M |
| 2015 | $3.64B | $446.16M | $652.12M |
| 2016 | $3.72B | $409.33M | $490.15M |
| 2017 | $3.87B | $436.83M | $502.72M |
| 2018 | $3.97B | $354.4M | $326.1M |
| 2019 | $4.09B | $479.45M | $528.29M |
| 2020 | $4.17B | $497.84M | $452.63M |
| 2021 | $4.29B | $688.37M | $715.37M |
| 2022 | $4.58B | $549.5M | $529.5M |
| 2023 | $4.89B | $540.71M | $698.27M |
| 2024 | $5B | $493.2M | $618.93M |
| 2025 | $4.53B | $564.7M | $645.14M |
| 2026 | $4.7B | $501.24M | $562.2M |
Revenue by region
Where Amdocs Limited generates its revenue.
- North America (Mainly United States)66%
- Rest of world19%
- Europe16%
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| North America (Mainly United States) | $2.79B | $3.1B | $3.31B | $3.33B | $2.98B | 65.8% |
| Rest of world | $874.39M | $894.47M | $877.42M | $952.8M | $844.25M | 18.6% |
| Europe | $622.78M | $582.19M | $703.14M | $726.23M | $705.11M | 15.6% |
| Total revenue | $4.29B | $4.58B | $4.89B | $5B | $4.53B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Sep 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 24 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.